Unmet Needs and Emerging Challenges in Multiple Myeloma

Topic Information

Dear Colleagues,

We are pleased to invite submissions for this Topic entitled "Unmet Needs and Emerging Challenges in Multiple Myeloma".

Multiple myeloma (MM) ranks as the second most prevalent hematological malignancy worldwide. Although substantial progress has been achieved in therapeutic options, multiple myeloma remains incurable. Key obstacles toward curative therapy include heterogeneity observed across phase III clinical trials and the lack of real‑world datasets that can reflect its broad clinical and molecular diversity. These limitations hinder accurate prognostic assessment and restrict the development of optimized personalized treatment strategies. Widely adopted prognostic systems such as R‑ISS integrate clinical and molecular parameters for risk stratification. Nevertheless, these existing models are associated with well‑recognized knowledge gaps and technical constraints. Moreover, they fail to capture important non‑genomic adverse prognostic factors, including extramedullary disease and circulating tumor cells. To enable clinicians to deliver appropriate risk‑adapted therapy for individual patients, comprehensive integration of clinical, biological and molecular signatures is urgently required. Advanced tools such as artificial intelligence (AI) offer promising approaches to achieve this goal. This Topic aims to gather recent research advances concerning the molecular pathogenesis of MM. It focuses on improved risk‑stratification frameworks, the integration of multi‑dimensional biological data, and emerging targeted therapies, with the ultimate objective of advancing personalized treatment toward becoming standard clinical practice for patients living with multiple myeloma.

Potential topics of interest include, but are not limited to:

• Application of genomics and proteomics in deciphering MM pathogenesis and drug‑resistance mechanisms, together with the identification of novel therapeutic targets and biomarker‑driven treatment approaches;
• Roles of multiple myeloma‑associated microbiomes in discovering novel biomarkers and therapeutic candidates;
• Implementation of bioinformatics and artificial intelligence (including machine learning) for big‑data and multi‑omics integration, as well as the construction of predictive models to support clinical management of MM patients;
• Precision‑medicine‑oriented strategies for patients with high progression risk, covering early‑intervention schemes and personalized therapeutic modalities;
• Clinical value of survival‑ and progression‑risk prediction for patient management and clinical outcomes, including risk‑adapted therapeutic strategies and quality‑of‑life assessment.

We welcome both original research articles and review papers. All submitted manuscripts will go through the standard peer‑review process.

Dr. Chung Hoow Kok
Dr. Cindy H. S. Lee
Dr. Claudio Cerchione
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Antibodies antibodies	3.3	4.9	2012	22.7 Days	CHF 1800	Submit
Current Issues in Molecular Biology cimb	4.1	5.0	1999	15.5 Days	CHF 2400	Submit
Current Oncology curroncol	3.6	6.1	1994	22.6 Days	CHF 2200	Submit
Hematology Reports hematolrep	1.9	2.3	2009	26.3 Days	CHF 1600	Submit
International Journal of Molecular Sciences ijms	5.6	10.0	2000	17.5 Days	CHF 2900	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Related Topic

Published Papers